Free Daily Podcast Summary
Retina Matters: Daily Summaries Delivered
by Astellas Pharma
Welcome to “Retina Matters," where eye care professionals come together to share their insights, experiences, and discuss the latest in treatment for retinal diseases – tune in and stay ahead of the curve.Please see episode description for Important Safety Information and visit bit.ly/4l9n7oP for full Prescribing Information.For U.S. Healthcare Professionals Only.MAT-US-IZE-2025-00225 06/25
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 4 weeks ago18 min
Partnership in Practice: A Collaborative Approach to GA Care
Geographic atrophy (GA) care is about more than treating a disease. In this episode, host Weslie Hamada, OD, FAAO, sits down with Veeral S. Sheth, MD, MBA, FACS, FASRS and Esther Kim, MD, FASRS, to discuss the role of partnership in GA management. Drawing from their experiences in Astellas’ “Partners in Protection” campaign, which highlights the real stories of retina specialists and patients with GA, they explore how trust, education and shared decision-making can help patients and physicians navigate the treatment journey together. For U.S. healthcare providers only. IMPORTANT SAFETY INFORMATION AND INDICATION CONTRAINDICATIONS IZERVAY® (avacincaptad pegol intravitreal solution) is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation. WARNINGS AND PRECAUTIONS Endophthalmitis and Retinal Detachments Intravitreal injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management. Neovascular AMD In the GATHER1 and GATHER2 clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD. Increase in Intraocular Pressure Transient increases in intraocular pressure (IOP) have been observed after an intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed as needed. ADVERSE REACTIONS Most common adverse reactions (incidence >5% and occurred with frequency >2% vs. sham) reported in patients receiving IZERVAY for up to 24 months in GATHER2: conjunctival hemorrhage, blurred vision, increased IOP, wet AMD, punctate keratitis, and eye pain. INDICATION IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Visit show webpage or https://bit.ly/izervayprescribinginfo for Full Prescribing Information. To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com. © 2026 Astellas Pharma Inc. or its affiliates. All trademarks are the responsibility of their respective owners. MAT-US-IZE-2026-00751 08/26
- Jun 29, 202617 min
Rethinking GA: A Clinical Shift Toward Earlier Detection and Management
Geographic atrophy (GA) management is rapidly evolving. In this episode, host Weslie Hamada, OD, FAAO, sits down with retina specialist David Chin Yee, MD, to discuss how therapies are changing the way clinicians identify and approach GA. From imaging-based risk assessment to referral coordination and treatment considerations, they examine opportunities for proactive management to help slow the progression of GA. For U.S. healthcare providers only. IMPORTANT SAFETY INFORMATION AND INDICATION CONTRAINDICATIONS IZERVAY® (avacincaptad pegol intravitreal solution) is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation. WARNINGS AND PRECAUTIONS Endophthalmitis and Retinal Detachments Intravitreal injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management. Neovascular AMD In the GATHER1 and GATHER2 clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD. Increase in Intraocular Pressure Transient increases in intraocular pressure (IOP) have been observed after an intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed as needed. ADVERSE REACTIONS Most common adverse reactions (incidence >5% and occurred with frequency >2% vs. sham) reported in patients receiving IZERVAY for up to 24 months in GATHER2: conjunctival hemorrhage, blurred vision, increased IOP, wet AMD, punctate keratitis, and eye pain. INDICATION IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Visit podcast webpage or https://bit.ly/izervayprescribinginfo for Full Prescribing Information To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com. MAT-US-IZE-2026-00580 05/26
- Jun 4, 202619 min
From Trial to Treatment: Bridging the Gap with OLE Data in GA Management
In this episode of Retina Matters, host Weslie Hamada, OD, FAAO, sits down with renowned retina specialist Arshad Khanani, MD, to take a closer look at what the open label extension (OLE) trial tells us about the treatment of geographic atrophy (GA). From added clinical nuance to real-world decision-making, they unpack how emerging insights are shaping a more informed, forward-looking approach to GA care. For U.S. healthcare providers only. IMPORTANT SAFETY INFORMATION AND INDICATION CONTRAINDICATIONS IZERVAY® (avacincaptad pegol intravitreal solution) is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation. WARNINGS AND PRECAUTIONS Endophthalmitis and Retinal Detachments Intravitreal injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management. Neovascular AMD In the GATHER1 and GATHER2 clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD. Increase in Intraocular Pressure Transient increases in intraocular pressure (IOP) have been observed after an intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed as needed. ADVERSE REACTIONS Most common adverse reactions (incidence >5% and occurred with frequency >2% vs. sham) reported in patients receiving IZERVAY for up to 24 months in GATHER2: conjunctival hemorrhage, blurred vision, increased IOP, wet AMD, punctate keratitis, and eye pain. INDICATION IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Visit show website or https://bit.ly/IZERVAY_PI for Full Prescribing Information To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com. MAT-US-IZE-2026-00483 04/26
About Retina Matters
Welcome to “Retina Matters," where eye care professionals come together to share their insights, experiences, and discuss the latest in treatment for retinal diseases – tune in and stay ahead of the curve.Please see episode description for Important Safety Information and visit bit.ly/4l9n7oP for full Prescribing Information.For U.S. Healthcare Professionals Only.MAT-US-IZE-2025-00225 06/25
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Retina Matters in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Retina Matters daily summary?
It's a free AI-powered email that summarizes new episodes of Retina Matters as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Retina Matters podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Retina Matters product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Astellas Pharma.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
What topics does Retina Matters cover?
Retina Matters covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Retina Matters summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.